. [eighty two] to evaluate the efficacy, security and tolerability of Cannabidiol as an adjunct therapy coupled with anti-epileptic prescription drugs within the patients suffering from tuberous sclerosis complicated whose commonest neurological symptom is epilepsy. In this particular scientific demo review, soon after remedy with Cannabidiol, resp